Overview

Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

Status:
Completed

Trial end date:
2004-07-01

Target enrollment:

Participant gender:

Summary

The primary objective is to evaluate the effect of 9 weeks treatment with either telmisartan or ramipril on NO bioavailability in the renal vasculature, measured as renal plasma flow (RPF) in response to NG-monomethyl-L-arginine (LNMMA) infusion.

Phase:

Phase 4

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Ramipril
Telmisartan